Universal Peace Federation Convenes Think Tank 2022 Rally of Hope
9.9.2021 18:51:00 EEST | Business Wire | Press release
A wide range of challenges stand in the way of building a stable and relatively peaceful global order for the 21st Century. Recent events related to the U.S. withdrawal from Afghanistan underscore this fact.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210909005818/en/
Dr. Hak Ja Han Moon, co-founder of the Universal Peace Federation addressing the global audience during the virtual 6th Rally of Hope and the launching of “THINK TANK 2022” (Photo: Business Wire)
Of critical importance to the geopolitical dynamics of our time is the ongoing crisis on the Korean Peninsula, which impacts East Asia and the rest of the world. While efforts toward peace have prevented another war in Northeast Asia, the potential for conflict still remains and would involve the U.S., China, Russia, and Japan. It is time for a new strategy to move toward reconciliation and cooperation on the Korean Peninsula.
Who: Think Tank 2022 Rally of Hope online is sponsored by the Universal Peace Federation (upf.org)
When: Sunday, September 12, 2021, 2:30 a.m. CET, Europe & Middle East (Live broadcast from South Korea) or Replay/Highlights: September 12, 2021, 6:00 PM CET
Where: Join the Live Event September 12th, at 02:30 AM (CET)
through this link: https://www.peacelink.live/online/
Join the Highlight Event September 12th, at 06:00 PM (CET)
through Zoom link: http://www.zoom.rallyofhope.eu/
or Live Facebook: http://www.facebook.rallyofhope.eu/
What: Inaugurated in 2020, the Rally of Hope is a series of live-streamed online productions using advanced augmented reality technology to connect millions of global viewers. Featuring prominent world leaders and captivating entertainment, the Rally of Hope is uplifting, actionable and faith-based.
Why: This new and unique program empowers the ordinary citizen who seeks meaningful change in their personal life, family, community, and even globally, by participating in a movement which transcends political, religious, racial, and ideological boundaries.
Previous Rallies of Hope have provided a platform for top experts to speak about the complex issues facing our planet, including: climate change, geopolitical hotspots, challenges of the coronavirus pandemic, honoring veterans of the Korean War on its 70th anniversary, the role of faith in peacebuilding, and much more.
The theme of the Think Tank 2022 Rally of Hope is “Steps Toward Peace in Asia: Focus on Reconciliation and Cooperation on the Korean Peninsula.” Although the Armistice Agreement brought an end to the hostilities, the Korean Peninsula continues to be a “storm center” for peace and security in the region. World leaders will speak about the risks and opportunities of resolving issues on the Korean Peninsula and steps toward peace in Asia.
Keynote Speakers: Kingdom of Cambodia Prime Minister Hun Sen, European Commission President
José Manuel Barroso (2004-2014), Republic of the Philippines President Gloria Macapagal Arroyo (2000-2010), Republic of India Prime Minister H.D. Deve Gowda (1996-1997), Trinidad and Tobago President Anthony Thomas Aquinas Carmona (2013-2018), and Republic of Serbia President Nataša Mićić (2002-2004). UPF Co-Founder Hak Ja Han Moon will offer a special message of hope in her Founder’s Address.
Find out more about the Rally of Hope & Think Tank 2022 here: https://www.rallyofhope.eu
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005818/en/
Contact information
Media:
Peter Zoehrer, UPF Media Relations - Europe & Middle East
+43 (0)6645238794
media@europe.upf.org
UPF.ORG & EUME.UPF.ORG
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom